Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 61,265 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Karimah Es Sabar also recently made the following trade(s):

• On Thursday, April 2nd, Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock. The shares were sold at an average price of $32.00, for a total value of $240,928.00.
• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05.

Capricor Therapeutics Stock Performance

CAPR opened at $32.11 on Friday. Capricor Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The company has a market capitalization of $1.85 billion, a P/E ratio of -14.21 and a beta of 0.48. The stock has a fifty day moving average of $27.38 and a 200-day moving average of $19.01.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, equities research analysts predict that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. B. Riley Financial increased their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Oppenheimer raised their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Farther Finance Advisors LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $28,000. Parkside Financial Bank & Trust bought a new position in Capricor Therapeutics in the third quarter valued at approximately $36,000. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares in the last quarter. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $43,000. Finally, GoalVest Advisory LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth $59,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.